Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study

Abstract Background Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) have a poor prognosis and limited therapeutic options. Immune checkpoint inhibitors (ICIs) are effective in patients with tumor progression < 6 months following first-line, platinum-based c...

Full description

Bibliographic Details
Main Authors: Agathe Vienne, Laetitia Collet, Thomas Chevalier, Christian Borel, Magalie Tardy, Florence Huguet, Sandrine Richard, Sebastien Salas, Esma Saada-Bouzid, Jerome Fayette, Amaury Daste
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Cancer
Subjects:
Platinum chemotherapy
Head and neck
Immune checkpoint inhibitors
Diseases free interval
Online Access:https://doi.org/10.1186/s12885-023-11133-5

Internet

https://doi.org/10.1186/s12885-023-11133-5

Similar Items